UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Implantation depth of balloon‐expandable transcatheter heart valves and risks for permanent pacemaker implantation and midterm adverse events

Catheterization and cardiovascular interventions, 2023-12, Vol.102 (7), p.1301-1310

2023

Volltextzugriff (PDF)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

Breast cancer research and treatment, 2021-05, Vol.187 (1), p.155-165

2021

Volltextzugriff (PDF)

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

The lancet oncology, 2019-06, Vol.20 (6), p.862-876

2019

Volltextzugriff (PDF)

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

The lancet oncology, 2018-01, Vol.19 (1), p.127-138

2018

Volltextzugriff (PDF)

Mixed effects models but not t-tests or linear regression detect progression of apathy in Parkinson's disease over seven years in a cohort: a comparative analysis

BMC medical research methodology, 2024-08, Vol.24 (1), p.183-8

2024

Volltextzugriff (PDF)

Levodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning

Parkinsonism & related disorders, 2024-09, Vol.126, p.107054, Article 107054

2024

Volltextzugriff (PDF)

SMZ/SNZ and gibberellin signaling are required for nitrate-elicited delay of flowering time in Arabidopsis thaliana

Journal of experimental botany, 2018-01, Vol.69 (3), p.619-631

2018

Volltextzugriff (PDF)

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial

JAMA oncology, 2022-07, Vol.8 (7), p.1047

2022

Volltextzugriff (PDF)

Accurate long-read sequencing identified GBA1 as major risk factor in the Luxembourgish Parkinson’s study

NPJ Parkinson's Disease, 2023-11, Vol.9 (1), p.156-156, Article 156

2023

Volltextzugriff (PDF)

Comprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism

NPJ Parkinson's Disease, 2024-03, Vol.10 (1), p.68-68, Article 68

2024

Volltextzugriff (PDF)

Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome

The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (3), p.759-768

2024

Volltextzugriff (PDF)

Integrating digital gait data with metabolomics and clinical data to predict outcomes in Parkinson’s disease

NPJ digital medicine, 2024-09, Vol.7 (1), p.235-16, Article 235

2024

Volltextzugriff (PDF)

Gut microbiome is not associated with mild cognitive impairment in Parkinson’s disease

NPJ Parkinson's Disease, 2024-04, Vol.10 (1), p.78-78, Article 78

2024

Volltextzugriff (PDF)

Author Correction: Accurate long-read sequencing identified GBA1 as major risk factor in the Luxembourgish Parkinson’s study

NPJ Parkinson's Disease, 2023-12, Vol.9 (1), p.168-168, Article 168

2023

Volltextzugriff (PDF)

Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B

Nature (London), 2011-11, Vol.479 (7373), p.401-405

2011

Volltextzugriff (PDF)

US mutual fund swing pricing proposal what can we learn from Europe?

The Investment Lawyer, 2016-01, Vol.23 (1), p.32

2016

Volltextzugriff (PDF)

Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer

Pathologie biologie (Paris), 2005-06, Vol.53 (5), p.277

2005

Volltextzugriff (PDF)

Adjuvant chemotherapy for Dukes B2 and C colon cancer combining 5-fluorouracil and folinic acid with or without carboplatin. Feasibility and comparison between standard and chronomodulated deliveries

Pathologie biologie (Paris), 2005-06, Vol.53 (5), p.281

2005

Volltextzugriff (PDF)

Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study

Pathologie biologie (Paris), 2005-06, Vol.53 (5), p.273

2005

Volltextzugriff (PDF)

Étude de faisabilité (Phase I–II) d'une quadruple combinaison associant le 5-fluorouracile, l'acide folinique et le carboplatine à de l'irinotecan administrés en infusion chronomodulée pour le traitement du cancer colorectal avancé

Pathologie biologie (Paris), 2005-06, Vol.53 (5), p.277-280

2005

Volltextzugriff (PDF)

Étude de faisabilité (Phase I-II) d'une quadruple combinaison associant le 5-fluorouracile, l'acide folinique et le carboplatine à de l'irinotecan administrés en infusion chronomodulée pour le traitement du cancer colorectal avancé: Numéro spécial sur la chronobiologie

Pathologie biologie (Paris), 2005, Vol.53 (5), p.277-280

2005

Volltextzugriff (PDF)

Chimiothérapie adjuvante pour le cancer du colon de stades Dukes B2 et C comportant du 5-fluorouracile et de l'acide folinique, avec ou sans carboplatine. Faisabilité et comparaison d'une administration standard à une administration chronomodulée

Pathologie biologie (Paris), 2005-06, Vol.53 (5), p.281-284

2005

Volltextzugriff (PDF)

Chimiothérapie adjuvante pour le cancer du colon de stades Dukes B2 et C comportant du 5-fluorouracile et de l'acide folinique, avec ou sans carboplatine. Faisabilité et comparaison d'une administration standard à une administration chronomodulée: Numéro spécial sur la chronobiologie

Pathologie biologie (Paris), 2005, Vol.53 (5), p.281-284

2005

Volltextzugriff (PDF)

Chronothérapie associant le 5-fluorouracile, l'acide folinique, et le carboplatine en première ligne thérapeutique dans le cancer colorectal métastatique. Une étude de phase 2

Pathologie biologie (Paris), 2005-06, Vol.53 (5), p.273-276

2005

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)

Sprache

Englisch
(19)
Französisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Humans
(10)
Female
(8)
Middle Aged
(8)
Aged
(7)
Neurosciences & Neurology
(6)
Biomedicine
(5)
Male
(5)
Neurology
(5)
Biomedical And Life Sciences
(4)
Drug Administration Schedule
(4)
Neurosciences
(4)
Oncology
(4)
Pathology
(4)
Patients
(4)
692/617/375/1718
(3)
Adult
(3)
Ambulatory Medicine
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Implantation depth of balloon‐expandable transcatheter heart valves and risks for permanent pacemaker implantation and midterm adverse events

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia

Mixed effects models but not t-tests or linear regression detect progression of apathy in Parkinson's disease over seven years in a cohort: a comparative analysis

Levodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning

SMZ/SNZ and gibberellin signaling are required for nitrate-elicited delay of flowering time in Arabidopsis thaliana

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial

Accurate long-read sequencing identified GBA1 as major risk factor in the Luxembourgish Parkinson’s study

Comprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism

Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome

Integrating digital gait data with metabolomics and clinical data to predict outcomes in Parkinson’s disease

Gut microbiome is not associated with mild cognitive impairment in Parkinson’s disease

Author Correction: Accurate long-read sequencing identified GBA1 as major risk factor in the Luxembourgish Parkinson’s study

Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B

US mutual fund swing pricing proposal what can we learn from Europe?

Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer

Adjuvant chemotherapy for Dukes B2 and C colon cancer combining 5-fluorouracil and folinic acid with or without carboplatin. Feasibility and comparison between standard and chronomodulated deliveries

Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study

Étude de faisabilité (Phase I–II) d'une quadruple combinaison associant le 5-fluorouracile, l'acide folinique et le carboplatine à de l'irinotecan administrés en infusion chronomodulée pour le traitement du cancer colorectal avancé

Étude de faisabilité (Phase I-II) d'une quadruple combinaison associant le 5-fluorouracile, l'acide folinique et le carboplatine à de l'irinotecan administrés en infusion chronomodulée pour le traitement du cancer colorectal avancé: Numéro spécial sur la chronobiologie

Chimiothérapie adjuvante pour le cancer du colon de stades Dukes B2 et C comportant du 5-fluorouracile et de l'acide folinique, avec ou sans carboplatine. Faisabilité et comparaison d'une administration standard à une administration chronomodulée

Chimiothérapie adjuvante pour le cancer du colon de stades Dukes B2 et C comportant du 5-fluorouracile et de l'acide folinique, avec ou sans carboplatine. Faisabilité et comparaison d'une administration standard à une administration chronomodulée: Numéro spécial sur la chronobiologie

Chronothérapie associant le 5-fluorouracile, l'acide folinique, et le carboplatine en première ligne thérapeutique dans le cancer colorectal métastatique. Une étude de phase 2

Suchergebnisse filtern